Related Experiment Video
Updated: Aug 7, 2026
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer
Yuding Wang1, Shawn Dason, Bobby Shayegan
1Division of Urology, McMaster Institute of Urology, Hamilton, Ontario, Canada.
Abstract:
Abiraterone acetate (AA) is a selective irreversible inhibitor of CYP 17, a key enzyme in androgen biosynthesis. The efficacy and safety of AA in improving survival and quality of life in metastatic castration resistant prostate cancer (mCRPC) has been demonstrated in two landmark clinical trials (COU-AA-301 and COU-AA-302). This article will review the rationale, pharmacology, clinical indications and contraindications, administration, and adverse effects of AA administration in mCRPC.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019